Physician profile
April T Rogers
NPI 1245280866
$2,806.62
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,233 · 2022: $1,435 · 2023: $53.44 · 2024: $84.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,188.85 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $400.58 | 2021-2023 | Relistor |
| Ironwood Pharmaceuticals, INC | $293.99 | 2021-2023 | Linzess |
| Janssen Biotech, INC. | $198.11 | 2021-2022 | |
| Qol Medical, LLC | $137.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.51 | 2021-2022 | |
| Daiichi Sankyo INC. | $108.78 | 2021-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $67.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.57 | 2021 | |
| Braintree Laboratories, INC. | $38.66 | 2022 | |
| Ardelyx, INC. | $32.76 | 2022 | |
| Redhill Biopharma INC. | $31.49 | 2021 | |
| Celgene Corporation | $29.91 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $27.40 | 2021 | |
| Gilead Sciences, INC. | $24.04 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15.27 | 2023 | |
| Nestle Healthcare Nutrition INC. | $13.53 | 2021 | |
| Amgen INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.